Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

By G. Kelloff, John M. Hoffman, B. Johnson, H. Scher, B. Siegel, E. Cheng, B. Cheson, J. O’Shaughnessy, K. Guyton, D. Mankoff and 5 more. Clinical Cancer Research, 2005

674 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/6181cef9a93164f0a8bb438e85a6e2c83187cc9a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Radiology, Nuclear Medicine and Imaging

1. C. V. Dang
2. Robert A. Gatenby
3. Robert James Gillies

Citations in the corpus

• A systematic review of the factors affecting accuracy of SUV measurements. (2010, background): “Other Biologic Factors FDG will accumulate in tissue in proportion to the rate of glucose utilization [2].”
• Causes and Consequences of Increased Glucose Metabolism of Cancers (2008, background): “This was comprehensively reviewed in 2001 (51) and discussed within the context of drug development in 2005 (52).”
• From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy (2016, background): “BPTES inhibition of hGA(124-551), a truncated form of human kidneytype glutaminase.”